Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 7.45 7.30 7.60 7.45 7.45 7.45 12,107 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.1 -2.7 - 10

Evgen Pharma Share Discussion Threads

Showing 1651 to 1674 of 1850 messages
Chat Pages: 74  73  72  71  70  69  68  67  66  65  64  63  Older
DateSubjectAuthorDiscuss
10/10/2019
14:05
I agree with your timeline for the news. LTH are also derisking as they watch previous profits evaporate.The share price is now below my average and represents 13.3% of my portfolio. I'm happy to divert other profits, as & when, into the lower price.
90005nelson
10/10/2019
13:41
Hi Nobby/Nelson.. Ive got to say Im not particularly �baffled� by the price movement, which seems to be following a well-trodden path between news to support of either 13.5p or 15p (broken), however, I am a little concerned that someone in some lab somewhere may have a shifter of something, although by no means saying this is the case; just a worry. I believe news is probably later in October to mid-November, so maybe it�s simply being walked down - although to do that, they need sellers (unless they�re trading between MMs to create an illusion) If these trades are valid, then someone, or some people , are certainly selling batches of rather large chunks. I see that there has been no Holdings RNS about the main holders, so at the moment it is pure guesswork - that people are de-risking/over-exposed/ want money for other things etc and feel that news isn�t coming until November. The other option is a leak, although maybe the Volume traded doesn�t equate to that.
pennyfalls
10/10/2019
11:02
I have to say I am a bit baffled by the recent price movement. Somebody clearly wants out for a reason which is beyond me as I don't think it is possible that anybody knows the result of the blinded trial yet. I agree that we probably won't get the results until November; cleaning up of data bases and data analysis always takes longer than expected in my experience. However, I can't really see why a short delay should cause such a pronounced fall.
nobbygnome
09/10/2019
22:15
Looks to me like the market isn't expecting results in October. So people worrying feeling over-exposed are reducing to a level they're comfortable holding at and also using the newly available funds for other shares.
90005nelson
09/10/2019
15:56
I’m a little concerned by some of the largish sells in recent days/weeks. I do wonder if someone has a sniff about the results direction? Today’s £23K was a sell, but posted as a buy as it was a delayed trade posting - and a couple of other £7Ks at a similar time. Could be people de-risking, MMs swapping shares between each other, or the possibility of a direction of travel leaking slowly? (Although to be fair, the same direction of travel chart-wise has preceded every other major rise)
pennyfalls
09/10/2019
10:39
Had a little top-up this morning
90005nelson
07/10/2019
17:02
Hi Pennyfalls, Thanks for your PM. I have sent a reply; apologies for the delay in getting back to you.
diamondstar1
04/10/2019
20:31
Must say there’s been some terrific knowledge on this board, and very lucky to have some dedicated Biotech people giving insight like Nobby, Timbo and Diamondstar. Been looking through some of their past posts regarding other shares, and makes for very interesting and insightful reading. Thanks to everyone else, Nelson et al, who’ve brought good discussion here too and Blakeysangel for such openness x
pennyfalls
03/10/2019
20:17
FAO Diamondstar.. sent you a Private Message, Cheers
pennyfalls
29/9/2019
17:27
Diamond star, There is no placebo as trial works like this, I was taking tamoxifen for 3 years, it stopped working, so added SFX01 with Tamoxifen and now it has kicked Tamoxifen back into action. So all the trial participants were on a drug that failed and STEM was tried to see if it would kick start the drug again. Hence no placebo because the drugs weren’t working so we couldn’t of stayed on the drug without STEM.. am I rambling lol.
blakeysangel
29/9/2019
17:15
I believe number 1) is false and number 2) is true. All the indications, shows delay mainly due to extra workload dataset. Which in turn means the mortality percentage (40%) has decreased to closer to 20% which in turn means that SFX-01 is a life saver in SAH trial, which in turn means that the secondary endpoint data is vital for it to keep its integrity.
90005nelson
29/9/2019
15:51
1) 40% of patients die within 30 days.2). we will fully maintain the blinded integrity of the secondary endpoint data, which in this trial are particularly important as they will form the basis of the primary endpoints in subsequent studies.3). Only one of the above statements can be true not both.
90005nelson
29/9/2019
12:44
The trial recruited a total of 104 patients, split into two arms in a randomised, double-blind, placebo-controlled trial.Wonder what the mathematical conundrum needed to be solved?
90005nelson
29/9/2019
12:12
Anyone worked out, Evgen has 20%+ more data than anticipated.?The clinical team is now focussed on the cleaning, validation and analysis of the large volume of data collected in this trial.
90005nelson
29/9/2019
07:22
Although the cynics might say that nimodipine is so ineffective it is about equivalent to a placebo!
nobbygnome
29/9/2019
07:20
>> diamond It is not a placebo controlled trial in SAH. The placebo group are getting nimodipine which is the current standard of care. The active group are getting the same plus sulforaphane. When you have a life threatening or severe condition clinical trials are never done without the standard of care.
nobbygnome
28/9/2019
22:01
Hi everyone, Ethics or otherwise? I think that since nothing else worked for Stage 4 Breast cancer, no placebo was required as the trial was already using a type of placebo .. the fact that nothing else worked was already the placebo IMO - and since this was life-saving/extending rather than proving parameters , this info wan't needed yet. However, as they narrow the targets for the next breast cancer trials, which will aim at earlier stage efficacy, then this will be more strict with tighter controls
pennyfalls
28/9/2019
14:07
Unethical to run a clinical trial with placebo in Metastatic Breast Cancer? Yet, ethical to run a placebo controlled trial in Subarachnoid Haemorrhage? I’m sorry... I don’t buy the unethical argument. The breast cancer study was on top of Standard of Care. How can we interpret the study results, when we don’t have a good yardstick to compare to?
diamondstar1
28/9/2019
12:28
Primary endpoint timeline is more important than than the secondary endpoint
90005nelson
28/9/2019
11:42
SAH trial had a flaw, the statisticians would have picked it up and so would have the clinicians. 40% of patients die within 30 days and for the survivors c.50% will have long-term cognitive impairmentThey would have compelling evidence, by 5th to 18th March 2019 . They had no choice but to delay releasing results.The previous month EVG had printed in February 2019 (Q1) they they would release primary endpoint data in Q2 . There you go
90005nelson
28/9/2019
11:39
Very simply it would be unethical to do so
dave444
28/9/2019
11:30
Other medications not working, I knew what I meant
90005nelson
28/9/2019
11:29
Participants were resistant to other medications
90005nelson
28/9/2019
11:08
Yes, agreeing with your points raised Pennyfalls. New to Evgen, and information gathering from my side. Presumably, the potential bias may be introduced by Investigator knowledge of ultrasound blood flow results, rather than PK results (which should be totally blinded). I fully agree that disclosure of primary and secondary simultaneously is best for the commercial perspective and potential deals. Also, an accurate assessment of neurological/cognitive effects and minimisation of bias - is essential for accurate sample size planning for the Phase 3. Can I ask a question here - why did Evgen design a Ph 2 trial in breast cancer patients without placebo-control? Seems a bit suboptimal; I fully support the SAH study design.
diamondstar1
Chat Pages: 74  73  72  71  70  69  68  67  66  65  64  63  Older
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191210 02:31:23